CD274 and triple-negative breast carcinoma: However, about 1 out of 5 triple-negative breast cancer patients expresses PD-L1 protein, thus only a small subset of triple-negative patients can benefit from the combinatorial administration of pembrolizumab and chemotherapy (reviewed in [14,15]).